A top-10 pharma company ran four oncology molecules through the platform over eighteen months — a checkpoint inhibitor in growth, a targeted therapy at launch, an ADC in Phase III, and a bispecific in Phase II. By the fourth molecule onboarded, Ground Truth generation dropped from eleven days to four. Cross-molecule competitive signals were routing automatically. Project setup time dropped 60%. And cross-molecule insights were surfacing that no single-molecule engagement could have produced — including a competitive approval that simultaneously affected two molecules' strategies, detected and routed to both teams the same day.